ArticleGene therapy2008
Configurations of a two-tiered amplified gene expression system in adenoviral vectors designed to improve the specificity of in vivo prostate cancer imaging.
Article in Gene therapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy.Theranostics · 2022Article
- A PCA3 gene-based transcriptional amplification system targeting primary prostate cancer.Oncotarget · 2016Article
- Molecular-genetic imaging of cancer.Advances in cancer research · 2014Review
- A molecular imaging system based on both transcriptional and genomic amplification to detect prostate cancer cells in vivo.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Molecular imaging of prostate cancer: PET radiotracers.AJR. American journal of roentgenology · 2012Review
- Experimental models to study lymphatic and blood vascular metastasis.Journal of surgical oncology · 2011Review
- Titration of variant HSV1-tk gene expression to determine the sensitivity of 18F-FHBG PET imaging in a prostate tumor.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2009Article
- Phase I study of noninvasive imaging of adenovirus-mediated gene expression in the human prostate.Molecular therapy : the journal of the American Society of Gene Therapy · 2008Article
- Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis.Cancer research · 2008Article
- Molecular Imaging of Prostate Cancer.Radiographics : a review publication of the Radiological Society of North America, IncReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Effective treatment for recurrent, disseminated prostate cancer is notably limited. We have developed adenoviral vectors with a prostate-specific two-step transcriptional amplification (TSTA) system that would express therapeutic genes at a robust level to target metastatic disease. The TSTA system employs the prostate-specific antigen (PSA) promoter/enhancer to drive a potent synthetic activator, which in turn activates the expression of the therapeutic gene. In this study, we explored different configurations of this bipartite system and discovered that physical separation of the two TSTA components into E1 and E3 regions of adenovirus was able to enhance androgen regulation and cell-discriminatory expression. The TSTA vectors that express imaging reporter genes were assessed by noninvasive imaging technologies in animal models. The improved selectivity of the E1E3 configured vector was reflected in silenced ectopic expression in the lung. Significantly, the enhanced specificity of the E1E3 vector enabled the detection of lung metastasis of prostate cancer. An E1E3 TSTA vector that expresses the herpes simplex virus thymidine kinase gene can effectively direct positron emission tomography (PET) imaging of the tumor. The prostate-targeted gene delivery vectors with robust and cell-specific expression capability will advance the development of safe and effective imaging guided therapy for recurrent metastatic stages of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.